Scarica l'app Stockscreener
153.87
3.11%
4.64
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVMD Giù?
Forum
Previsione
Revolution Medicines Inc Borsa (RVMD) Ultime notizie
Pancreatic Cancer Drug Milestone Affirms Why Revolution Medicines Inc. (RVMD) is a Hot Stock to Buy - Yahoo Finance
Revolution Medicines: Strong Data, Big Market (Rating Upgrade) - Seeking Alpha
Why is Revolution Medicines (RVMD) up 9.3% since last earnings report? - MSN
Number of shareholders of Revolution Medicines, Inc. – NASDAQ:RVMDW - TradingView
‘Pharma Bro’ Martin Shkreli Defends Revolution Medicines’ Pancreatic Cancer Study Data: ‘Progress Compounds’ - Stocktwits
Bernstein initiates coverage of Revolution Medicines (RVMD) with market perform recommendation - MSN
Daraxonrasib’s Phase 3 Pancreatic Cancer Survival Data Might Change The Case For Investing In RVMD - Yahoo Finance
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Erasca, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
RVMD: Insider files Form 144 to sell 10,000 shares (NASDAQ: RVMD) - Stock Titan
Can Revolution Medicines Be a Game-Changer Stock? - Yahoo Finance
RVMD Maintained by Evercore ISI Group -- Price Target Raised to $220 - GuruFocus
Revolution Medicines Inc. Warrant (RVMDW) Edges Higher Amid Modest Trading ActivityFibonacci Entry Signals - newsline.com
Tango shares surge on early pancreatic cancer combination data - The Pharma Letter
UBS Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $175 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Revolution Medicines (RVMD) Reports Promising Data on Vopimetost - GuruFocus
Tango Therapeutics Stock Soars 53% After ’Unprecedented’ Data on Pancreatic Cancer Treatment - Barron's
Revolution Medicines (RVMD) Strengthens PDAC Position with New D - GuruFocus
Is Revolution Medicines (RVMD) The Best Biotech Stock According to Billionaire Stanley Druckenmiller? - Insider Monkey
Revolution Medicines, Inc. (RVMD) Stock Analysis: Unlocking a 24.86% Upside Amidst Biotech Breakthroughs - DirectorsTalk Interviews
Total equity of Revolution Medicines, Inc. – XETR:42Z - TradingView
Debt to assets ratio of Revolution Medicines, Inc. – XETR:42Z - TradingView
ETFs Investing in Revolution Medicines, Inc. Stocks - TradingView
(RVMD) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Earnings call transcript: Revolution Medicines Q1 2026 focuses on strong cash position - Investing.com
Revolution Medicines (RVMD) Drops 4% as Biotech Sector Faces Renewed PressureTrading Ideas - newsline.com
Revolution Medicines in the spotlight for earnings post-trial win By Investing.com - Investing.com Nigeria
Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report? - Yahoo Finance
Novo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial exec - Endpoints News
California Pharma Co. Tests Breakthrough Cancer Drug, Cuts Death Risk 60% - Streetwise Reports
Revolution Medicines is up 97% this year: Here are the bull and bear cases for this soaring biotech stock - MSN
Revolution Medicines Stock Surges on Promising Cancer Drug Data - IndexBox
Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock. - The Motley Fool
Redwood City company develops pill to treat pancreatic cancer, and trial results are promising - NBC Bay Area
What RevMed’s pancreatic cancer drug meant for one patient - statnews.com
Assessing Revolution Medicines (RVMD) Valuation After Positive Daraxonrasib Phase 3 Results At ASCO 2026 - Yahoo Finance
For pancreatic cancer patients, an exciting drug can feel out of reach - statnews.com
Does Revolution Medicines’ pancreatic cancer drug have even greater potential? - statnews.com
Revolution Medicines in the spotlight for earnings post-trial win - Investing.com
Revolution Medicines reports phase 3 win in pancreatic cancer - MSN
Revolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer TreatmentSlideshow (NASDAQ:RVMD) 2026-06-03 - Seeking Alpha
Uprising in pancreatic space more than Revolution - BioWorld News
ASCO’s biggest winners showcased a new era of cancer innovation - BioSpace
ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck - BioSpace
'It's still working': More are living with cancer as era of targeted drugs takes hold - marketscreener.com
Video New results from clinical trial of 'groundbreaking' pancreatic cancer treatmentABC News - ABC News - Breaking News, Latest News and Videos
Revolution Medicines: More Landmark Data Doesn't Dispel Doubts Around Valuation (RVMD) - Seeking Alpha
Revolution Medicines' Cancer Drug Darax Seen Holding Lead Over Rivals, RBC Says - Moomoo
A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $165 to $215 - Moomoo
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), IN8bio (INAB) and PolyPid (PYPD) - The Globe and Mail
2.26%
1.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):